YANTAI, China, June 26, 2025 /PRNewswire/ -- Raythink Technology Co., Ltd. ("Raythink"), an innovator in the thermal imaging industry, has launched its latest ultra-high...
− Results show delivery of high radiation doses to tumours compared with normal organs.− Observed normal organ absorbed dosimetry results may allow administration of...
− Results show delivery of high radiation doses to tumours compared with normal organs.− Observed normal organ absorbed dosimetry results may allow administration of...
As the CU Cancer Center celebrates its 40th anniversary, here are five ways it helped to change detection and treatment of the disease.
AURORA, Colo.,...
Rising Demand for Natural Ingredients, Growing Health & Wellness Trends, and Expanding Applications in Cosmetics and Pharmaceuticals Drive 8% CAGR Growth Across Global Markets
REDDING,...
Rising Demand for Natural Ingredients, Growing Health & Wellness Trends, and Expanding Applications in Cosmetics and Pharmaceuticals Drive 8% CAGR Growth Across Global Markets
REDDING,...
SOMERSET, N.J., June 23, 2025 /PRNewswire/ -- ProCure Proton Therapy Center reminds area residents about the critical importance to men of prostate-specific antigen (PSA)...
ASPIRE pivotal Level-1 PMA IDE study evaluated PearlMatrix vs. local autograft in single-level TLIF procedures:- Demonstrated statistically superior fusion speed;- Achieved over twice as...
Garching / Munich, Germany, and Lausanne, Switzerland - June 23, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and Debiopharm, a Swiss-based, global biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced that the first patient was imaged in a new study arm of a five-part, Phase 1/2 clinical trial (formerly GaLuCi™) (NCT05706129) evaluating the theranostic pair ITM-94/ITM-91 for identification and treatment of patients who have unresectable, locally advanced or metastatic solid tumors. As a new component of a broad clinical development plan for ITM-91/ITM-94, Part D of the trial will evaluate the effectiveness of ITM-94 in classifying indeterminate renal mass as either ccRCC or non-cancerous.
GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it entered into a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for potential acquisitions, marketing and other general corporate purposes.
Poinciana, Fl, June 20, 2025 (GLOBE NEWSWIRE) -- SanMelix, the company behind BeeCure Radiation Burn Relief Cream, is excited to announce the addition of Mr. Ajay Dhaul to our Board of Directors and Executive Leadership team in the role of Chief Strategy & Growth Officer, effective June 9, 2025.
LEXINGTON, Mass., June 20, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) today announced that the Committee for Medicinal Products for Human Use (CHMP) of...